In a previous study, we hypothesized that some type 2 diabetes mellitus susceptible genes may be up/downregulated in white blood cells (WBC) of Otsuka Long-Evans Tokushima Fatty (OLETF) rats, reflecting their up/down-regulation in major insulin-target tissues such as the liver before the onset of diabetes. We identified 57 potential candidate genes for predicting diabetes. In this study, we examined this hypothesis further by extending the experimental conditions from before the onset (6 weeks) to after the onset (24 weeks) of diabetes that type 2 diabetes mellitus susceptible genes are co-regulated in WBC, reflecting their expression in the liver. Using rat oligo DNA microarrays, we found that 48 genes are up/down-regulated in OLETF rats compared to control Long-Evans Tokushima Otsuka (LETO) rats in WBC and liver under fasting or insulin administration conditions. Twenty nine and 33 genes were up/down-regulated in both WBC and livers, respectively, under fasting and insulin administration conditions, respectively. Eight out of 29 genes in fasting condition and 12 out of 33 genes in insulin administration conditions have been reported to be type 2 diabetes mellitus susceptible genes and the remainder have not been reported to be related to type 2 diabetes mellitus. These results support our hypothesis that the expression levels of type 2 diabetes mellitus related genes in WBC are reflective of those in the liver after the onset of diabetes.
base pairs of the human genome. A knowledge of all the human genes and their functions may allow effective preventative measures, and have an impact on drug discovery and development processes. 1) Under these circumstances, a genetic diagnosis would become possible, if disease-related genes could be identified and alteration of their expressions could be estimated before the onset of the disease.
In this study, we focused on type 2 diabetes mellitus, since it is considered to be a multi-factorial disorder that includes both genetic and environmental factors. Genome wide screening has been performed for genes responsible for type 2 diabetes mellitus in adipose, liver and skeletal muscle. [2] [3] [4] The recent development of DNA microarray technology has made it possible to analyze gene expression on a genome-wide basis, to determine the gene expression profile and its relationship between organs can also be analyzed. 5) These studies provide information on disease states at the molecular and genetic levels.
However, it is difficult to perform a genetic analysis on type 2 diabetes mellitus in a clinic using tissue samples such as liver, adipose and muscle. Therefore, we proposed an approach to the genetic diagnosis of type 2 diabetes mellitus that involves, by measuring the up/down regulation of some type 2 diabetes mellitus related genes using white blood cells (WBC), since the peripheral blood is an accessible source of cells and circulating WBC can be viewed as a surveillance of the body. The gene expression responses of circulating WBC can potentially provide an early warning of potential threats and can be used for the diagnosis of only infections but other diseases as well. 6) We reported that the expression of the calpain 10 gene in WBC is significantly decreased after the onset of type 2 diabetes in Otsuka-Long-Evans Tokushima Fatty (OLETF) rats, compared to Long-Evans Tokushima Otsuka (LETO) control rats. OLETF rats are used as a model of type 2 diabetes, and a decrease in gene expression was found in liver, adipose and muscle. 7) We also performed a genome-wide gene expression analysis using OLETF and LETO rats before onset and 57 genes were found to have the same up/down gene expression pattern between WBC and the liver. 8) In this study, we hypothesize there are some type 2 diabetes mellitus related genes which are up/down-regulated between WBC and liver after the onset of diabetes. A genome wide gene expression analysis was performed by comparing WBC and liver using an oligo DNA microarray.
MATERIALS AND METHODS
Animals Twenty-four-week old male OLETF and LETO rats were generously donated by the Tokushima Research Institute, Otsuka Pharmaceutical (Tokushima, Japan).
9) The rats were housed with free access to water and food at 22°C and 58% humidity with light from 7:00 to 19:00. All animal protocols were approved by the institutional animal care and research advisory committee of the Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Tissue Sampling Twenty-four-week old male OLETF rats were used as an after onset model, based on an intraperitoneal glucose tolerance test (IPGTT). After overnight fasting, whole blood and liver tissue were collected as fasting samples. Porcine insulin (SIGMA, St. Louis, MO, U.S.A.) was injected intraperitoneally into 24-week old rats (5 U/kg BW) after overnight fasting, and rats were cervically dissociated 1 h after insulin administration. Whole blood and liver were collected after decapitation. 10) All experiments were carried out without the use of an anesthetic, because diethyl ether affects serum glucose concentrations.
Isolation of Total RNA Whole blood was collected from the carotid artery and total RNA was extracted from WBC using a PAXgene Blood RNA kit (PreAnalytiX, Hombrechtikon, Switzerland). The liver was harvested and rapidly frozen in liquid nitrogen, and all samples were stored at Ϫ80°C until used for assay. Total RNA from stocked liver samples were extracted using the TRIzol reagent (Invitrogen, Carlsbad, CA, U.S.A.) and purified using an RNeasy Mini Kit combined with a RNase-free DNase Digest Set (QIA-GEN, Hilden, Germany) for the degradation of genomic DNA in total RNA samples, and total RNA extracted from four rats (5 mg each) were then pooled into one sample for normalizing a individual differences, followed by a gene expression analysis in both tissues by oligo DNA microarrays.
11) Total RNA extracts from WBC and liver were stored at Ϫ80°C until used in the assays.
DNA Microarray Experiments In this study, 500 ng aliquots of pooled RNA samples under the respective conditions were labeled using the Agilent Low RNA Input Fluorescent Linear Amplification Kit (Product No. 5184-3568, Agilent Technologies, Palo Alto, CA, U.S.A.) according to the manufacture's instructions. After checking the labeling efficiency, 1 mg aliquots of Cy3-labeled LETO cRNA and Cy5-labeled OLETF cRNA were mixed and then hybridized to Agilent Rat Oligo Microarrays (G4130A) using the manufacturer's hybridization protocol (Product No. 5184-3568, Agilent Technologies, Palo Alto, CA, U.S.A.). After the washing step, the microarray slides were analyzed using an Agilent Microarray scanner (G2565AA). These experiments were carried out in duplicate using exchanged dye-labeled cRNA probes (i.e., Cy3 and Cy5 dye-swapping experiments). Data were analyzed using the Agilent Feature Extraction software (Version A.6.1.1).
Hierarchical Clustering The expression levels of genes in WBC and livers were observed for both fasting and insulin administration. The expression levels of the genes under these four conditions were screened. Each sample type is represented by the logarithm (Log 10 ) of the fluorescence signal ratio (Cy5 signal to Cy3 signal), referred to hereafter as the "log ratio" for simplicity. In this rat oligo DNA microarray, each spot (also referred to as "feature") contains copies of a nucleic acid sequence (60 bases) that is complementary to some segment of the DNA sequence of the gene that the spot detects. Since a spot corresponds to one of the partial sequences of the target gene instead of the entire sequence, a single gene can, in some cases, correspond to more than one spot on the DNA microarray. A set of the four expression levels of a gene is called an expression profile of the gene and the similarity between the expression patterns of two genes is identified as the Euclidean distance between their expression profiles, in this analysis. Note that a lower distance value means that two genes share a similar expression profile.
Screening Criteria of Concurrently Regulated Genes between WBC and Liver Genes which were differentially expressed in OLETF rats compared to LETO rats were selected for fasting and insulin administrated conditions. The data were statistically analyzed by the ANOVA test and genes with p valuesϽ0.01 were selected. Dye-swapping experiment data (LETO rat RNA sample labeled with Cy5 and OLETF rat RNA samples labeled with Cy3) were also used to extract highly reproducible spots. Among these genes, only those that were simultaneously up/down regulated both in WBC and liver were screened under the respective conditions.
Quantitative Reverse Transcription PCR cDNA was prepared from 400 ng aliquots of pooled RNA samples from OLETF or LETO using TaKaRa RNA PCR Kit (AMV) Ver. Each gene-specific primer set was designed using Primer Express Software Ver 2.0 (Applied Biosystems, Lincoln Centre Drive Foster City, CA, U.S.A.) and these sequences are shown in Table 1 . PCR was performed using the following program; 95°C for 15 s and 60°C for 1 min, after 10 min pre-incubation at 95°C in an Applied Biosystems 7500 Real Time PCR System. All samples were run in triplicate and data were calculated using the comparative Ct method and are expressed as a ratio to glyceraldehydes-3-phosphate dehydrogenase (GAPDH), as a reference.
RESULTS

Gene Expression Profiles in WBC and Liver of OLETF and LETO Rats under Fasting and Insulin Administration
The gene expression profiles under fasting conditions and insulin administration in WBC and livers are shown in Fig. 1 . Each row corresponds to a gene and the four columns correspond to WF, LF, WI, and LI, as described in the figure legend. One thousand ninety two genes were detected as sig- Tables 2 and 3. nificant signals at least under one condition. To extract some of the highly reproducible spots, a dye-swapping data (LETO rat RNA sample labeled with Cy5 and OLETF rat RNA samples labeled with Cy3) were also used. These genes were further analyzed using hierarchical clustering to group genes with similar expression patterns in their expression profiles ( Fig. 1 ). These genes were subsequently divided into four main clusters. The genes in cluster 1 showed a tendency to be decreased in WBC of the OLETF rats (green color in columns WF and WI), with a relatively small alteration in the liver (black color in columns LF and LI) under both conditions. Cluster 2 contains genes that are down-regulated under both conditions in the liver (green color in columns LF and LI), with a relatively small alteration in WBC. Cluster 3 contains genes that are up-regulated under both conditions in the liver (red color in columns LF and LI), with a relatively small alteration in WBC. Cluster 4 contains genes in WBC that are up-regulated under both conditions (red color in columns WF and WI). Under both conditions for OLETF rats in the diabetic state, in WBC, the number of differentially down-regulated genes were more numerous than those of differentially up-regulated genes. On the other hand, in the liver under both conditions, a similar number of genes were up-regulated or down-regulated. These results suggest that, in the diabetic state, differences exist in the regulation of gene expression in WBC vis-à-vis the liver. In the following analysis, differences in the expression patterns depending on the different conditions in both tissues were examined. Insulin signals could be generated in both WBC and the liver by the administration of insulin (compare column WF and were down-regulated and 297 genes were up-regulated (Table  3 , lower list).
Screening of Concurrently Regulated Genes in WBC and Liver of OLETF Rats
In the following analysis, genes that were concurrently altered in WBC and the liver of OLETF were screened. Twenty-nine genes under fasting and 33 genes under insulin administration were detected (Fig. 2,  Table 4 ). Since 14 genes were detected in both stimulations, forty-eight were screened in both conditions. Under fasting conditions, in cluster 1, sixteen genes were down-regulated in both WBC and the liver (colored green in column WF, LF, Fig. 2a) . In cluster 2, six genes were down-and up-regulated in WBC and the liver, respectively (colored green and red in columns WF and LF). In cluster 3, four genes were up-regu- Twenty genes (top 10 down-and up-regulated genes) in liver are shown. The scale of genes alteration represent as log 10 ( OLETF/LETO ) ratio value. These genes were selected as described in Material and Methods. lated in both tissues (colored red in column WF, LF). In cluster 4, three genes were up-and down-regulated in WBC and the liver, respectively (colored red and green in columns WF and LF). Under insulin administration, in cluster 1, seventeen genes were down-regulated in both WBC and the liver (colored green in column WI, LI , Fig. 2b ). In cluster 2, three genes were up-and down-regulated in WBC and the liver, respectively (colored red and green in columns WI and LI). In cluster 3, eight genes were down-and up-regulated in WBC and the liver (colored green and red in columns WI, LI). In cluster 4, five genes were up-regulated in both tissues (colored red in columns WI and LI). The expression of a total of 48 out of 1092 genes were simultaneously altered in WBC and the liver. The selected genes in Fig. 2 with expression ratios on a log 10 scale and the putative biological functions of their encoded proteins are also summarized (Table 4) . Fourteen out of 48 genes reported to be type 2 diabetes mellitus related genes were screened, while no information related to type 2 diabetes mellitus for the remaining 34 genes. Quantitative Reverse Transcription PCR Quantitative reverse transcription PCR was performed to confirm the microarray data. We focused on genes that were screened in both conditions. In these genes, we selected two genes, acylCoenzyme A binding domain containing 4 (Acbd4) and transcobalamin 2 (Tcn2). As shown in Fig. 3 , the relative expression of Acbd4 was increased in WBC and the liver of 24-week old OLETF rats under fasting and insulin administration conditions, compared with LETO rats of the same age, which is consistent with the microarray data. The relative expression of Tcn2 was decreased in WBC and increased in the liver of 24-week old OLETF rats under both conditions compared with LETO rats of the same age, which is consistent with the microarray data.
DISCUSSION
WBC are easily obtained and thus useful as specimens for diagnosis. In addition, WBC can be used to determine individual variability and certain pathological conditions. For example, variations in gene expression in WBC from healthy individuals were analyzed and genes whose expression varies depending on genetic factors, sex, and age were identified. 12, 13) A genome-wide expression analysis was applied for patients and healthy persons and the possible use of WBC for clinical diagnosis was examined. 14) Personalized medicine based on gene expression profiles of WBC is expected to be carried out in the near future.
Preliminary clinical applications of the global gene expression analysis of WBC to the diagnosis of neurological diseases in humans have been reported. 15) In fact, the expression of marker genes was reported to be significantly up-regulated in WBC as well as caudate nuclei in Huntington's disease patients.
16) These reports demonstrate the presence of genes whose expression is altered at the transcriptional level in common in WBC and the brain although the number of genes was not given. Thus, it is possible to predict and understand pathological conditions using blood mRNAs.
We examined this possibility independently for type 2 diabetes mellitus. First, we demonstrated that the expression of the calpain 10 gene, a diabetes-related gene, was significantly down-regulated in WBC and the liver of precritical OLETF rats, indicating the possibility of predicting gene expression patterns in other organs by that in WBC. 7) We then performed a genome-wide expression analysis of WBC and the liver of OLETF rats before onset to identify novel candidate genes for predicting the onset of type 2 diabetes. Fifty seven genes were identified as genes whose expression was altered both in WBC and the liver, suggesting the possibility of predicting and understanding pathological conditions by a genome-wide analysis of WBC mRNAs. In this study, we created gene expression profiles for WBC and the liver of OLETF rats after onset. 339 and 410, and 354 and 665 genes were detected as significant, reproducible spots, in WBC and the liver under fasting, and in WBC and the liver after insulin administration, respectively. The number of detected genes was similar in WBC under the two conditions, while the number increased by 1.6-fold in the liver upon insulin administration. However, a dynamic alteration in expression pattern (i.e. increase or decrease) was not observed in the liver (Fig. 1, LF and LI columns) , possibly due to the acquisition of insulin-resistance after the onset of type 2 diabetes.
We found that 29 and 33 genes (total of 62 genes including 14 identical genes) were expressed differently in both WBC and the liver of OLETF and LETO rat strains under fasting and after insulin administration, respectively (Table 4) . Before onset, fifty seven genes were found to be expressed differently in both WBC and the liver under the same conditions. 8) This suggests that altered expressions in WBC may reflect those in liver for these genes.
These 48 genes include 14 which are known to be related to type 2 diabetes (Table 4) . Among the 20 genes, 8 and 12 were detected under fasting and after insulin administration, respectively. Genes related to an immune response and lipid metabolism were also included in the 48 genes.
The interleukin 6 receptor gene was detected as a gene related to an immune response. The interleukin 6 receptor may affect pathological conditions of type 2 diabetes by complex formation with interleukin 6, the expression of which is elevated by hyperglycemia.
17) The LPS-induced TNF a gene is activated by a lipopolysaccharide in a murine cell line derived from macrophages. 18 ) TNF a is an important factor involved in the onset of diabetes and TNF a production in subjects with type 2 diabetes may contribute to insulin resistance. 19) Although the expression of the TNF a gene decreased in WBC and the liver (Table 4) , the elucidation of the regulation mechanism for the gene may link TNF a production with diabetes. The expression of the glutathione S-transferase theta 3 gene was altered in WBC and the liver. This gene may be involved in the pathogenesis since an association between a variant of glutathione S-transferase theta 1, and markers of inflammation and lipid peroxidation has been reported. 20) The function of the acyl-coenzyme A binding domain containing 4 is uncertain at this time. However, it may be related to lipid metabolism since acyl-coenzyme A is a key in lipid metabolism.
21) It would be of interest to examine the role of the protein encoded by this gene.
Expression of the gene for the FK506-binding protein 5 was altered. It has been reported that the induction of 51-kDa FK506-binding protein mRNA by glucocorticoids may be a suitable marker for assessing individual glucocorticoid sensitivity. 22) The transcobalamin 2 protein binds vitamin B12 and diabetic patients have a higher total B12 binding capacity and higher serum B12 levels. 23) Thus, these genes are potential markers for judging the onset and progression of diabetes.
We used an oligo DNA microarray for a comprehensive analysis of gene expression. The altered expression of the 48 genes selected in this study were checked in a dye-swapping experiment to ensure the reproducibility of the data. 24) Indeed, very similar tendencies in expression were observed with quantitative RT PCR and with the microarray analysis (Fig. 3) , indicating the reliability of the data. In this study, we found that 48 genes are up/down-regulated in OLETF rats compared to control LETO rats in WBC and the liver under fasting or insulin administered conditions. It will be necessary to analyze functions of these genes in vivo and studies concerning this are currently in progress with siRNAs. Based on the results obtained with the knockdown experiments, the diagnosis of type 2 diabetes by gene expression will pave the way to clinical applications.
